IC
CRBP icon

Ikarian Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Ikarian Capital’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-51,431
Closed -$607K – 181
2024
Q4 		$607K Sell
51,431
-233,284
-82% -$3.91M 0.08% 127
2024
Q3 		$5.87M Sell
284,715
-24,825
-8% -$1.27M 0.82% 29
2024
Q2 		$14M Sell
309,540
-249,731
-45% -$10.5M 2.44% 12
2024
Q1 		$21.9M Buy
559,271
+363,372
+185% +$8.96M 2.41% 8
2023
Q4 		$1.18M Hold
195,899
– – 0.11% 95
2023
Q3 		$1.32M Buy
195,899
+3,639
+2% +$25.2K 0.16% 93
2023
Q2 		$1.51M Hold
192,260
– – 0.24% 76
2023
Q1 		$1.4M Buy
192,260
+179,021
+1,352% +$783K 0.32% 63
2022
Q4 		$43.9K Hold
13,239
– – 0.01% 80
2022
Q3 		$66K Sell
13,239
-15,512
-54% -$109K 0.01% 101
2022
Q2 		$217K Sell
28,751
-4,503
-14% -$43.5K 0.04% 116
2022
Q1 		$530K Buy
33,254
+1,636
+5% +$21.7K 0.07% 135
2021
Q4 		$584K Hold
31,618
– – 0.09% 121
2021
Q3 		$968K Sell
31,618
-519
-2% -$20.5K 0.07% 157
2021
Q2 		$1.76M Hold
32,137
– – 0.14% 138
2021
Q1 		$1.9M Buy
32,137
+27,500
+593% +$1.81M 0.06% 203
2020
Q4 		$174K Buy
+4,637
New +$173K 0.01% 212

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ikarian Capital's CRBP Position: Q1 2025 in Review

Ikarian Capital sold out of Corbus Pharmaceuticals (CRBP) in Q1 2025, closing a stake of 51,431 shares — an estimated $607K sold.

Ikarian Capital first reported a position in CRBP in Q4 2020 and held it in 17 quarters. The position peaked at $21.9M in Q1 2024. 86 funds tracked by Wall St. Rank hold CRBP as of Q1 2025.

  • Ikarian Capital reported no remaining Corbus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 51,431 Corbus Pharmaceuticals shares in Q1 2025, an estimated $607K.
  • Ikarian Capital first reported a position in Corbus Pharmaceuticals in Q4 2020 and held it in 17 quarters.
  • Ikarian Capital's Corbus Pharmaceuticals position peaked at $21.9M in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.